Gilliam Joseph E sold $10.8M of GKOS

Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.

Original reporting
SEC EDGAR · Gilliam Joseph E
Published Aug 13, 2026, 11:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 60,000 shares on 2026-08-11 at $178.8900 to $180.4900, with holdings after the sale of 72,588 shares.

02

Market read

Traders may briefly reassess sentiment around GKOS due to insider selling, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, pre-planned personal needs, or option/RSU mechanics not captured here; traders should check for other recent insider activity and any concurrent company news.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-13 after trades dated 2026-08-11

Background

The article is a SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by its President and COO.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS COO sold 60,000 shares in open-market transactions totaling about $10.78M at ~$179.74 average.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader news flow.

Evidence & confidence

The filing is a primary-source Form 4 disclosure with transaction size and pricing, but it does not include new guidance, contracts, or regulatory/clinical catalysts.

Market effects

No clear sector read-through from a single insider sale without additional company-specific developments.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or tax-related, especially since it is not stated as part of a 10b5-1 plan, so it may not signal deteriorating fundamentals.

Key entities

  • GLAUKOS Corp

    Company whose insider transaction is disclosed via Form 4.

  • Gilliam Joseph E

    President and COO who sold 60,000 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.